Jun 8, 2021 4:10 pm EDT Ocuphire Announces Closing of $15 Million Registered Direct Offering Priced At-the-Market
Jun 8, 2021 8:00 am EDT Ocuphire Announces Appointment of Jay S. Pepose, M.D., Ph.D. to Its Board of Directors
Jun 4, 2021 9:04 am EDT Ocuphire Announces $15 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
May 20, 2021 7:30 am EDT Ocuphire to Host Key Opinion Leader Event on Nyxol® as a Potential New Treatment Option for Reversing Pharmacologically Induced Mydriasis
May 18, 2021 7:30 am EDT Ocuphire Granted Two New U.S. Patents Covering Late-Stage Drug Candidate Nyxol®, Including for the Treatment of Presbyopia
May 12, 2021 7:30 am EDT Ocuphire Completes Enrollment in VEGA-1 Phase 2 Clinical Trial Investigating Nyxol® in Combination with Low-Dose Pilocarpine for Treatment of Presbyopia
May 7, 2021 8:00 am EDT Ocuphire Announces Financial Results for the First Quarter 2021 and Provides Corporate Update
Apr 22, 2021 8:00 am EDT Ocuphire’s APX3330 for Retinal Diseases to be Presented at the 2021 Association for Research in Vision and Ophthalmology (ARVO) Virtual Annual Meeting
Apr 8, 2021 8:31 am EDT Ocuphire Initiates ZETA-1 Phase 2 Clinical Trial Investigating APX3330 in Diabetic Retinopathy
Apr 1, 2021 5:10 pm EDT Ocuphire Pharma, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)